APPLICATION OF COMPUTATIONAL METHODS IN DRUG DISCOVERY

P.L.Sujatha; K.Anbu Kumar; P.Devendran; S.P.Preetha; Manikkavasagan Ilangopathy3

doi:10.56093/ijvasr.v53i5.161975

Authors

P.L.Sujatha Librarian, Madras Veterinary College, Chennai
K.Anbu Kumar1 Assistant Professor, Bio informatic Centre, Madras Veterinary College, Chennai
P.Devendran Professor and Head, Bio informatics centre, Madras Veterinary College, Chennai
S.P.Preetha2 Associate Professor and Head, Dept. of Veterinary Pharmacology and Toxicology, Veterinary College and Research Institute, Salem
Manikkavasagan Ilangopathy3 Assistant Professor, Dept. of Food Safety and Quality Assurance, College of Food and Dairy Technology, Koduveli

https://doi.org/10.56093/ijvasr.v53i5.161975

Keywords:

In silico drug discovery, Computational Approach, Bioinformatics

Abstract

Rational drug design, is the inventive process of finding new medications based on knowledge of the biological target. Drug design involves the design of small molecules that are complementary in shape and charge to the bimolecular target to which they interact and therefore will bind to it. In the experiment based approach, drugs are discovered through trial and error. With high R&D cost and consumption, computational drug discovery helps scientists gain insight into drug receptor interactions and reduce time and cost. Scientists can predict whether the molecule will succeed or fail in the market. Currently, the process of drug designing increasingly relies on computer modeling techniques. This type of modeling is often referred to as computer-aided drug design. In computational drug discovery, different computational tools, methods, and software are used to simulate drug receptor interactions. Using computational drug discovery helps scientists gain insight into drug receptor interactions with less time and cost.

Downloads

Download data is not yet available.

References

Agu, P.C., Afiukwa, C.A., Orji, O.U. and Aja, P.M. (2023) Molecular docking as a tool for the discovery of molecular targets of nutraceuticals in diseases management. Scientific Reports, 13: 13398 .

Anderson, A.C. (2003). The process of structure-based drug design.Chemical Biology, 10(9): 787 - 797.

Badar, M.S., Shamsi, S., Ahmed, J., and Alam, M.A. (2022). Molecular Dynamics Simulations: Concept, Methods, and Applications. In: Rezaei, N. (eds) Transdisciplinarity. Integrated Science, Vol 5.Springer, Cham. https://doi. org/10.1007/978-3-030-94651-7_7

Chang, Y., Hawkins, B.A., Du, J.J., Groundwater, P.W., Hibbs, D.E. and Lai, F.A. (2022). Guide to In silico Drug Design. Pharmaceutics, 15(1): 49.

Ekins, S., Mestres, J. and Testa, B. (2007). In silico pharmacology for drug discovery: methods for virtual ligand screening and profiling. British Journal of Pharmacology, 152(1): 9 - 20.

Kapetanovic, I.M. (2008). Computer-aided drug discovery and development (CADDD). In silico-chemico-biological approach. Chemico-Biological Interactions, 171(2): 165 – 176. http:// dx.doi.org/10.1016/ j.cbi.2006.12.006.

Kwon, S., Bae, H., Jo, J. and Yoon, S. (2019) Comprehensive ensemble in QSAR prediction for drug discovery. BMC Bioinformatics 20, 521.

Lee, J.Y. and Kim, Y. (2005).Comparative homology modeling and ligand docking study of human catechol-O- methyltransferase for antiparkinson drug design. Bulletin of the Korean Chemical Society, 26: 379 – 385

Leelananda, S.P., Beilstein, J. and Lindert, S. (2016). Computational methods in drug discovery. Organic Chemistry, 12: 2694 – 2718. http://dx. doi. org/10.3762/bjoc.12.267.

MSF reveals cost of landmark TB clinical trial in push for drug-development cost transparency MSF (2024) https://www. msf.org/msf-reveals-cost-landmark-tb- clinical-trial-push-drug-development- cost-transparency

Muhammed, M.T, and Aki-Yalcin, E. (2019) Homology modeling in drug discovery: Overview, current applications, and future perspectives. Chemical Biology & Drug Design, 93(1):12-20.

Mullard, A. (2024) Eli Lilly spends $3.2 billion on Morphic's oral integrin inhibitor for inflammatory bowel disease. Nature Reviews Drug Discovery, 23(9):650.

Qing, X., Lee.X.Y., De Raeymaecker, J., Tame, J, Zhang, K., De Maeyer, M., and Voet, A. (2014) Pharmacophore modeling: advances, limitations, and current utility in drug discovery. Journal of Receptor, Ligand and Channel Research, 7:81-92

Sadybekov, A.V. and Katritch, V. (2023). Computational approaches streamlining drug discovery. Nature, 616(7958): 673- 685.

Schneider, G. and Fechner, U. (2005) Computer-based de novo design of drug-like molecules.Nature Reviews& Drug Discovery, 4:649–663.

Shaker, B., Ahmad, S., Lee, J., Jung, C. and NaIn, D. (2021). In silico methods and tools for drug discovery. Computers in Biology and Medicine, 137: 104851.

Sliwoski, G., Kothiwale, S., Meiler, J. and Lowe, E.W. (2014). Computational methods in drug discovery. Pharmacology, 66(1): 334 – 395.

Vyas, V.K., Ukawala, R.D., Ghate, M. and Chintha, C. (2012). Homology modeling a fast tool for drug discovery: Current perspectives. Indian Journal of Pharmaceutical Sciences, 74(1): 1 – 17.

Yu, W. and MacKerell, A.D. Jr. (2017) Computer-Aided Drug Design Methods. Methods in Molecular Biology,1520:85-106.